- Home
- EVAX vs LYRA Comparison
EVAX vs LYRA Comparison
Compare EVAX & LYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVAX
- LYRA
- Stock Information
- Founded
- EVAX 2008
- LYRA 2005
- Country
- EVAX Denmark
- LYRA United States
- Employees
- EVAX N/A
- LYRA N/A
- Industry
- EVAX Biotechnology: Biological Products (No Diagnostic Substances)
- LYRA Medical/Dental Instruments
- Sector
- EVAX Health Care
- LYRA Health Care
- Exchange
- EVAX Nasdaq
- LYRA Nasdaq
- Market Cap
- EVAX 15.1M
- LYRA 15.0M
- IPO Year
- EVAX 2021
- LYRA 2020
- Fundamental
- Price
- EVAX $2.61
- LYRA $6.58
- Analyst Decision
- EVAX Strong Buy
- LYRA Buy
- Analyst Count
- EVAX 2
- LYRA 2
- Target Price
- EVAX $10.00
- LYRA $16.00
- AVG Volume (30 Days)
- EVAX 121.3K
- LYRA 37.8K
- Earning Date
- EVAX 08-13-2025
- LYRA 08-13-2025
- Dividend Yield
- EVAX N/A
- LYRA N/A
- EPS Growth
- EVAX N/A
- LYRA N/A
- EPS
- EVAX N/A
- LYRA N/A
- Revenue
- EVAX $3,293,000.00
- LYRA $1,185,000.00
- Revenue This Year
- EVAX N/A
- LYRA N/A
- Revenue Next Year
- EVAX N/A
- LYRA $139.18
- P/E Ratio
- EVAX N/A
- LYRA N/A
- Revenue Growth
- EVAX 2555.64
- LYRA N/A
- 52 Week Low
- EVAX $1.20
- LYRA $3.81
- 52 Week High
- EVAX $17.75
- LYRA $37.50
- Technical
- Relative Strength Index (RSI)
- EVAX 49.56
- LYRA 33.89
- Support Level
- EVAX $2.56
- LYRA $7.77
- Resistance Level
- EVAX $3.03
- LYRA $8.37
- Average True Range (ATR)
- EVAX 0.20
- LYRA 0.54
- MACD
- EVAX -0.01
- LYRA -0.10
- Stochastic Oscillator
- EVAX 25.00
- LYRA 10.48
About EVAX Evaxion Biotech
Evaxion AS is in the field of oncology. It used the AI-Immunology platform.
About LYRA Lyra Therapeutics Inc.
Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioabsorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.